N-cyclopentylpentanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-cyclopentylpentanamide
• 化学式: C₁₀H₁₉NO
• mdl: MFCD03374326
• 分子量: 169.26
• InChiKey: NYZRJKPYBSCUGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] SYNTHESIS OF 2-BUTYL-3-(2'-(1-TRITYL-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)-1,3-DIAZASPIROL[4,4]-NON-ENE-4-ONE<br/>[FR] SYNTHESE DE 2-BUTYL-3-(2'-(1-TRITYL-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)-1,3-DIAZASPIRO[4,4]-NON-EN-4-ONE
  申请人：TEVA PHARMA

  公开号：WO2004072064A1

  公开（公告）日：2004-08-26

  Provided is a novel method of making 2-butyl-3-[[2'(1-trityl-1H-tetrazol-5-yl)biphen-4-yl]methyl]1,3-diazaspiro[4,4]non-1-ene-4-one, which can be converted to irbesartan. Also provided are methods of making irbesartan.

  提供了一种制备2-丁基-3-[[2'(1-三苯基-1H-四唑-5-基)联苯-4-基]甲基]1,3-二氮杂螺[4,4]壬-1-烯-4-酮的新方法，该方法可转化为厄贝沙坦。还提供了制备厄贝沙坦的方法。
• A new process for the preparation of irbesartan
  申请人：KRKA, tovarna zdravil, d.d., Novo mesto

  公开号：EP2194050A1

  公开（公告）日：2010-06-09

  A process for the preparation of Irbesartan or a pharmaceutically acceptable salt thereof comprising the step of coupling the 1-pentanamidocyclapentanecarboxamide of formula (V) with 4'-substituted methyl biphenyl-2-carbonitrile or 1-(4'-substituted methyl biphenyl-2-yl)-1H-tetrazole wherein tetrazole can be protected or unprotected to obtain the N-[(2'-cyanobiphenyl-4-yl)methyl]-1-pentanamidocyclopentanecarboxamide or N-[1-([2'-(1H-tetrazol-1-yl)biphenyl-4-yl]methylamino)methyl)cydopentyl]pentanamide wherein tetrazole can be protected or unprotected that is further processed to Irbesartan or a pharmaceutical acceptable salt thereof.

  制备厄贝沙坦或其药用可接受盐的方法包括以下步骤：将式（V）的1-戊酰胺环戊烷羧酰胺与4'-取代甲基联苯基-2-碳腈或1-(4'-取代甲基联苯基-2-基)-1H-四唑偶联，其中四唑可以被保护或未被保护，得到N-[(2'-氰基联苯基-4-基)甲基]-1-戊酰胺环戊烷羧酰胺或N-[1-([2'-(1H-四唑-1-基)联苯基-4-基]甲基氨基}甲基)环戊基]戊酰胺，其中四唑可以被保护或未被保护，进一步处理得到厄贝沙坦或其药用可接受盐。
• COMPOUNDS
  申请人：Respivert Ltd

  公开号：US20140249164A1

  公开（公告）日：2014-09-04

  The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.

  本发明涉及公式（I）的化合物，以及包含它们的组合物，以及化合物及其组合物在治疗中的应用，例如在治疗炎症性疾病，特别是呼吸道炎症性疾病方面的应用。本发明还涉及制备所述化合物的方法。
• Novel synthesis of 2-butyl-3-(2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)-1,3-diazaspiro[4.4]-non-ene-4-one
  申请人：——

  公开号：US20040242894A1

  公开（公告）日：2004-12-02

  Provided is a novel method of making 2-butyl-3-[[2′(1-trityl-1H-tetrazol-5-yl)biphen-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-ene-4-one, which can be converted to irbesartan. Also provided are methods of making irbesartan.

  本发明提供了一种新型的 2-丁基-3-[[2′(1-三苯甲基-1H-四唑-5-基)联苯-4-基]甲基]-1,3-二氮杂螺[4.4]壬-1-烯-4-酮的制造方法，该方法可将其转化为厄贝沙坦。还提供了制造厄贝沙坦的方法。
• Novel synthesis of 2-Butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one
  申请人：Dolitzky Ben-Zion

  公开号：US20060128967A1

  公开（公告）日：2006-06-15

  Provided is a novel method of making 2-butyl-3-[[2′(1-trityl- 1 H-tetrazol-5-yl)biphen-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-ene-4-one, which can be converted to irbesartan. Also provided are methods of making irbesartan.

  本发明提供了一种新型方法，用于制造 2-丁基-3-[[2′(1-三苯甲基-1-丁基) 1 2′(1-三苯甲基-1-四唑-5-基)联苯-4-基]甲基]-1,3-二氮杂螺[4.4]壬-1-烯-4-酮的新方法，该方法可转化为厄贝沙坦。还提供了制造厄贝沙坦的方法。